<span item_type="fundamental" item_id="fc2782fdcf9231843436938bd523d4a9" counter_id="ST/US/IBO" env="prod"></span><span item_type="announcement" item_id="549387998595060993" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 7 K.</p><p>EPS: As of FY2025 Q2, the actual value is USD -1.29.</p><p>EBIT: As of FY2025 Q2, the actual value is USD -15.63 M.</p><p></p><h3>Segment Revenue</h3><ul><li>Biotech retail sales revenue for the three and six months ended June 30, 2025 was $7,000, compared to $0 for the same periods in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1834105/000164117225023809/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Operating loss for the three months ended June 30, 2025 was - $1,153,000, compared to - $626,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1834105/000164117225023809/form10-q.htm"></span></li><li>Operating loss for the six months ended June 30, 2025 was - $2,165,000, compared to - $1,396,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1834105/000164117225023809/form10-q.htm"></span></li><li>Net loss for the three months ended June 30, 2025 was - $14,352,000, compared to - $884,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1834105/000164117225023809/form10-q.htm"></span></li><li>Net loss for the six months ended June 30, 2025 was - $15,631,000, compared to - $1,880,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1834105/000164117225023809/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used by operating activities for the six months ended June 30, 2025 was - $1,376,000, compared to - $867,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1834105/000164117225023809/form10-q.htm"></span></li><li>Net cash provided by investing activities for the six months ended June 30, 2025 was $1,000, consistent with the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1834105/000164117225023809/form10-q.htm"></span></li><li>Net cash provided by financing activities for the six months ended June 30, 2025 was $0, compared to $867,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1834105/000164117225023809/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The change in fair value of note payable, related party for the three and six months ended June 30, 2025 was - $12,942,000, compared to $0 for the same periods in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1834105/000164117225023809/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Impact BioMedical Inc. plans to monetize its intellectual properties and tightly control operating costs to continue as a going concern.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1834105/000164117225023809/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is actively seeking potential partners for further development and commercialization of its technologies, including Laetose and Functional Fragrance Formulation, worldwide.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1834105/000164117225023809/form10-q.htm"></span></li><li><strong>Priority</strong>: The company aims to leverage strategic partnerships to advance its biopharmaceuticals and consumer wellness offerings.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1834105/000164117225023809/form10-q.htm"></span></li></ul>

Impact BioMedical | 10-Q: FY2025 Q2 Revenue: USD 7 K